Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (vol 117, pg 3733, 2011)

Ibrahim A. R.; Eliasson L.; Apperley J. F.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (vol 117, pg 3733, 2011)

【24h】

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (vol 117, pg 3733, 2011)

机译：依从性差是长期接受长期治疗的慢性粒细胞白血病患者CCyR和伊马替尼治疗失败的主要原因（第117卷，第3733页，2011年）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2012年第24期|共1页
作者
Ibrahim A. R.; Eliasson L.; Apperley J. F.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (vol 117, pg 3733, 2011) [J] . Ibrahim A. R., Eliasson L., Apperley J. F. Blood: The Journal of the American Society of Hematology . 2012,第24期

机译：依从性差是长期接受长期治疗的慢性粒细胞白血病患者CCyR和伊马替尼治疗失败的主要原因（第117卷，第3733页，2011年）
2. Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy [J] . Lee Sung-Eun, Choi Soo-Young, Kim Soo-Hyun, Leukemia and lymphoma . 2018,第1a2期

机译：基线BCR-ABL1转录型E13A2和大的脾脏大小是慢性期慢性骨髓性白血病患者在伊马替尼治疗3个月后未能达到早期分子反应的慢性相位慢性骨髓性白血病患者的预测因子
3. Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study (vol 91, pg 679, 2017) [J] . Jonsson Sofia, Olsson Bob, Soderberg Jenny, Annals of hematology . 2017,第8期

机译：慢性骨髓白血病患者患者对伊马替尼治疗的良好粘附 - 单一中心观测研究（Vol 91，PG 679,2017）
4. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
5. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy [O] . Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, -1

机译：依从性差是长期接受长期治疗的粒细胞白血病患者CCyR和伊马替尼治疗失败的主要原因
6. Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy [O] . Lippert, Eric, Etienne, Gabriel, Mozziconacci, Marie-Joelle, 2010

机译：费城阳性细胞中Y染色体的丢失预示着慢性粒细胞白血病患者对甲磺酸伊马替尼治疗的不良反应

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (vol 117, pg 3733, 2011)

著录项

引文网络

相似文献

相关主题

期刊订阅